MME and hydrops fetalis: Despite a higher statistical power in the PARAGON-HF due to a longer follow-up (median 35 months compared to 26 months in the EMPEROR-Preserved), the addition of neprilysin inhibition reduced the composite endpoint of cardiovascular death and total hospitalizations for HF only by 13% (rate ratio, 0.87 [0.75–1.01]; p = 0.059), while adding empagliflozin reduced the same end point by 21% (rate ratio, 0.79 [0.68–0.92]; p = 0.003).